Oral corticosteroids in asthma and beyond: moving forward

Jeffrey Shi Kai Chan, Ruth B Murray, David Price* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

Abstract

As some of the earliest-known and most effective anti-inflammatory agents, corticosteroids have long been a part of the physicians’ armamentarium against asthma and other chronic inflammatory conditions. While inhaled corticosteroids (ICS) are the cornerstone of asthma therapy, both the Global Initiative for Asthma (GINA) and British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines recommended the use of oral corticosteroids (OCS) as intermittent therapy in severe acute asthmatic attacks and as maintenance therapy in selected patients with severe asthma refractory to inhaled therapies [1, 2]. More recently, OCS have also been recommended as an adjunct to biologic therapies
Original languageEnglish
Article number2200776
Number of pages5
JournalEuropean Respiratory Journal
Volume60
Issue number3
Early online date15 Sep 2022
DOIs
Publication statusPublished - 15 Sep 2022

Fingerprint

Dive into the research topics of 'Oral corticosteroids in asthma and beyond: moving forward'. Together they form a unique fingerprint.

Cite this